RCT looking at HRQoL with two kinds of ascetic drains in untreatable cirrhosis patients. The study will compare an alternative intervention, insertion of a palliative tunnelled long-term abdominal drain (Group 1 intervention - LTAD), to standard of care large volume paracentesis (Group 2 intervention - LVP) in the management of refractory ascites.

The aim of the Q-ABC study is to address the current paucity of information available to patients and clinicians facing treatment decisions where increasingly evidence is showing surgery and radiotherapy can provide equivalent overall survival.

This study is investigating if it is acceptable to people with HER2 positive secondary breast cancer with no history of brain metastases to be randomised to surveillance via MRI scanning versus no surveillance.

This project aims to design a programme the help people with bowel cancer who not very active to move more before and after thir bowel cancer surgery, which can help them feel better, recover faster, and even lower the chance of the cancer coming back. The team are working closely with patients, nurses, cancer support workers and other health experts to make sure the programme is easy to use, helpful, inclusive and fit's into people's lives.

There is interest worldwide about using a drug called a PARP inhibitor (PARPi) in people with BRCA 1 or BRCA 2 gene changes. These drugs already work in patients with cancer who have gene changes. We hope that PARP inhibitors given to those with gene changes who do not have cancer will stop a cancer developing. Before doctors can design a chemoprevention trial using this drug, we need to find out the preferences and acceptability of such a study. Initial insights gained from members of the public - in this instance women - will help with trial design and the sort of information required.